DMD and Duchenne muscular dystrophy: This has been shown to be clinically beneficial in different instances, including for the three FDA-approved ASOs for Duchenne muscular dystrophy, eteplirsen, golodirsen, and viltolarsen [19–21], which function by inducing exon skipping in the DMD transcript to produce a functional dystrophin protein that is otherwise lacking in the disease due to DMD gene mutations [40].